Keyphrases
Venous Thromboembolism
100%
Direct Oral Anticoagulants
72%
Thrombocytopenia
62%
Aspirin
61%
Atrial Fibrillation
60%
Platelets
60%
Anticoagulation
59%
Thrombosis
52%
Thrombin Generation
46%
Bleeding
45%
Low Molecular Weight Heparin
39%
Antiplatelet Therapy
39%
Procoagulant Potential
39%
Pregnancy Disorders
37%
Confidence Interval
37%
Clopidogrel
36%
In Cancer
35%
Cancer Patients
34%
Clinical Outcomes
34%
Endogenous Thrombin Potential
32%
Patients with Hematological Malignancies
32%
Bleeding Risk
31%
Apixaban
29%
Type 2 Diabetes Mellitus (T2DM)
28%
Population-based Cohort Study
27%
Arterial Thromboembolism
26%
Hazard Ratio
26%
Platelet Count
26%
Hematological Malignancies
23%
Platelet Adhesion
23%
Recurrent Venous Thromboembolism
22%
Dose Adjustment
21%
Platelet Inhibition
21%
Platelet Activation
20%
Immune Thrombocytopenic Purpura
20%
Chemotherapy
19%
Antithrombotic Therapy
19%
Hemostasis
19%
Patients with Cancer
19%
Antiplatelet Agents
19%
Flow Condition
19%
Cancer-associated Thrombosis
19%
Cumulative Incidence
19%
Type 2 Diabetic Patients
19%
Major Bleeding
18%
Cancer-related
18%
Malignant Superior Vena Cava Syndrome
18%
Fragility Hip Fracture
18%
COVID-19
18%
Percutaneous Coronary Intervention
18%
Medicine and Dentistry
Venous Thromboembolism
93%
Malignant Neoplasm
89%
Platelet
76%
Anticoagulation
74%
Thrombosis
64%
Thrombocytopenia
61%
Atrial Fibrillation
58%
Bleeding
49%
Direct Oral Anticoagulant
39%
Hematologic Malignancy
37%
Thrombin
32%
Antiplatelet
30%
Procoagulant
29%
Apixaban
28%
Cohort Analysis
27%
Maturity Onset Diabetes of the Young
27%
Arterial Thromboembolism
26%
COVID-19
24%
Diseases
23%
Deep Vein Thrombosis
21%
Thrombocyte Activation
20%
Blood Stasis
20%
Antithrombotic
20%
Thrombotic Thrombocytopenic Purpura
20%
Cancer
20%
Major Bleeding
18%
Blood Clot Lysis
18%
Superior Vena Cava Syndrome
18%
Factor XI
18%
Low Molecular Weight Heparin
16%
Disease Course
16%
Thromboprophylaxis
16%
Hazard Ratio
15%
Cancer Treatment
15%
Acetylsalicylic Acid
14%
Thrombocyte Adhesion
14%
Type 1 Diabetes
13%
Cumulative Incidence
13%
Non Small Cell Lung Cancer
13%
Thromboembolism
13%
Thrombocyte Transfusion
12%
Infection
12%
Antiphospholipid Antibody
12%
Phlebothrombosis
11%
Fibrinogen
11%
Antithrombotic Therapy
11%
Idiopathic Thrombocytopenic Purpura
11%
CHA2DS2-VASc Score
11%
Computer Assisted Tomography
10%
Adenosine Diphosphate
10%
Pharmacology, Toxicology and Pharmaceutical Science
Venous Thromboembolism
78%
Malignant Neoplasm
71%
Acetylsalicylic Acid
68%
Atrial Fibrillation
61%
Direct Oral Anticoagulant
55%
Antiplatelet
54%
Thrombocytopenia
46%
Thrombin
44%
Thrombosis
41%
Bleeding
41%
Non Insulin Dependent Diabetes Mellitus
36%
Clopidogrel
35%
Anticoagulant Agent
32%
Antithrombocytic Agent
31%
Cohort Study
29%
Arterial Thromboembolism
29%
Low Molecular Weight Heparin
28%
Procoagulant
28%
Adenosine Diphosphate
28%
Hematologic Malignancy
28%
Diseases
21%
Chemotherapy
21%
Hip Fracture
18%
Apixaban
18%
Thrombotic Thrombocytopenic Purpura
18%
Purinergic P2Y12 Receptor
15%
Acute Heart Infarction
14%
Antivitamin K
13%
Non Small Cell Lung Cancer
13%
Infection
13%
Arachidonic Acid
13%
Normal Human
13%
Flow Cytometry
12%
P-Selectin
12%
Polypharmacy
12%
Integrin
12%
Diabetes Mellitus
11%
Warfarin
11%
Antithrombotic Therapy
10%
SARS Coronavirus
10%
Acute Coronary Syndrome
10%
Disease Course
10%
Prasugrel
10%
Ticagrelor
10%
Brain Metastasis
10%
Brain Hemorrhage
10%
Insulin Dependent Diabetes Mellitus
9%
Vein Thrombosis
9%
Endometriosis
9%
Disease Severity
9%